1.Gastrointestinal ALK-positive anaplastic large cell lymphoma: a clinicopathological analysis of five cases.
Chinese Journal of Pathology 2023;52(8):785-790
Objective: To investigate the clinicpathological characteristics of ALK-positive anaplastic large cell lymphoma (ALCL) of the gastrointestinal tract, and to discuss its diagnosis and differential diagnosis. Methods: Five cases of gastrointestinal ALK-positive ALCL diagnosed and treated in Xijing Hospital of the Fourth Military Medical University, between 2011 and 2019 were collected. There were three male and two female patients, aged 5-42 years (mean 25 years). These patients clinically presented with fever and night sweats, weight loss, abdominal pain, abdominal mass, ulcers, bleeding, or intestinal obstruction, and underwent surgical resection of the tumors or endoscopic biopsy. The clinical manifestations, auxiliary examinations, histopathological characteristics, immunophenotypes and genetic alterations were analyzed. Results: In this cohort, one case was common type, two cases were monomorphic variant of common type, and two cases were small cell variant. The tumor cells in all cases expressed ALK, CD30, and one or more T lymphocyte markers, while all the markers of B lymphocyte and plasmacyte were negative. Clonality analysis showed that two cases had clonal T cell receptor (TCR) and immunoglobulin (Ig) gene rearrangement, one case had no clonal TCR but Ig gene rearrangement, and one case had no clonal TCR and Ig gene rearrangements. During the 4 to 67 months' follow-up, two patients died of the disease, two were alive with free of disease and one had a relapse. Conclusions: ALK-positive ALCL of the gastrointestinal tract is extremely rare, and has poor prognosis. Lymphoma originating from this site with CD30 and ALK-positive phenotypes may be considered to be ALCL; however differentiation from other tumors that had anaplastic features, expressed CD30 and or ALK, in particular, ALK positive large B-cell lymphoma is necessary.
Male
;
Female
;
Humans
;
Lymphoma, Large-Cell, Anaplastic/pathology*
;
Receptor Protein-Tyrosine Kinases/genetics*
;
Anaplastic Lymphoma Kinase
;
Gastrointestinal Tract/pathology*
;
Lymphoma, Large B-Cell, Diffuse/genetics*
2.Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma with COX7A2L-ALK Fusion: A Case Report and Literature Review.
Jiao YUAN ; Ruili PAN ; Wei ZHONG ; Mengzhao WANG
Chinese Journal of Lung Cancer 2023;26(4):319-324
Lung cancer is the most common in incidence and mortality worldwide. With the development of next generation sequencing (NGS) detection technology, more and more patients with rare anaplastic lymphoma kinase (ALK) fusion mutations were detected. A case of advanced lung adenocarcinoma with rare COX7A2L-ALK (C2:A20) fusion detected by NGS was reported in Peking Union Medical College Hospital, and all cases with rare ALK fusion mutations were searched from medical datebase from January 1, 2014 to March 31, 2021, to investigate the treatment of rare ALK fusion mutations with ALK inhibitors. The best response of the patient was assessed as partial response (PR) with Ceritinib treatment. By literature review, 22 cases of rare ALK fusion were reported in 19 articles. Combined with this case, 23 cases were analyzed. The objective response rate (ORR) was 82.6% (19/23) and disease control rate (DCR) was 95.7% (22/23) for rare ALK fusions patients treated with ALK inhibitors. Lung adenocarcinoma patients with rare ALK fusion could benefit from ALK inhibitors.
.
Humans
;
Anaplastic Lymphoma Kinase/genetics*
;
Lung Neoplasms/diagnosis*
;
Crizotinib
;
Adenocarcinoma of Lung/genetics*
;
Protein Kinase Inhibitors/pharmacology*
;
Oncogene Proteins, Fusion/genetics*
4.Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer.
Chinese Journal of Lung Cancer 2018;21(9):686-691
Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutations and ALK rearrangements are mutually exclusive, but isolated cases or small sample research with concomitant EGFR and ALK alterations have been constantly reported. The co-occurrence of EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular, the frequency of EGFR/ALK co-alterations was about 1%, however, little has been known about clinicopathologic feature and treatment. This review summarized published case report, EGFR and ALK alterations are common in female, Asian origin, never smoker, IV stage, and denocarcinomas. First-line treatment can choose EGFR or ALK tyrosine kinase inhibitors (TKIs). However, studies about the origin and resistance mechanism in EGFR/ALK co-alterations are little, require more experimental and clinical research.
.
Anaplastic Lymphoma Kinase
;
Carcinoma, Non-Small-Cell Lung
;
diagnosis
;
enzymology
;
genetics
;
ErbB Receptors
;
genetics
;
Humans
;
Lung Neoplasms
;
diagnosis
;
enzymology
;
genetics
;
Mutation
;
Prognosis
;
Receptor Protein-Tyrosine Kinases
;
genetics
5.Anaplastic lymphoma kinase-translocation renal cell carcinoma: clinical and pathological analysis.
Shi Hao DI ; Xiao Tong WANG ; Qiu Yuan XIA ; Zhen Feng LU ; Heng Hui MA ; Ru Song ZHANG ; Xuan WANG ; Qiu RAO
Chinese Journal of Pathology 2022;51(1):28-32
Objective: To investigate the clinicopathological features, molecular characteristics, differential diagnosis and prognosis of anaplastic lymphoma kinase (ALK)-translocation renal cell carcinoma. Methods: Two cases of ALK-translocation renal cell carcinoma diagnosed from January 2011 to December 2020 were retrospectively analyzed to characterize their morphological features, immunohistochemical expression and prognosis. Multiple molecular studies including fluorescence in situ hybridization (FISH), reverse transcriptase-polymerase chain reaction (RT-PCR), and next-generation sequencing were performed to characterize the genetic alterations. Results: Two patients included one male and one female, with 59 and 57 years old, respectively. Morphologically, case 1 resembled collecting duct carcinoma or renal medullary carcinoma, which demonstrated tubular, microcapsule and reticular structures, with a remarkable myxoid background and lymphocytes infiltration; case 2 resembled Xp11.2 translocation renal cell carcinoma or type 2 papillary renal cell carcinoma, which demonstrated tubular papillary and focal solid structures, with flocculent cytoplasm and many foamy histiocytes, but without myxoid background and lymphocytes infiltration. Immunohistochemistry showed strongly positive expression of ALK. CK7, E-cadherin, vimentin, PAX8 and CD10 showed various degrees of expression, and other antibodies were nonreactive. A variety of molecular assays showed definite ALK gene translocation, with rare VCL-ALK gene fusion (VCL exon and 16-ALK exon 20) in case 1, and EML4-ALK gene fusion (EML4 exon and 2-ALK exon 20) in case 2. Conclusions: ALK-translocation renal cell carcinoma is rare with various morphological features, and is easy to miss and misdiagnose. The characteristic ALK expression and molecular detection of ALK translocation are helpful for diagnosing this type of renal cell carcinoma.
Anaplastic Lymphoma Kinase/genetics*
;
Carcinoma, Renal Cell/genetics*
;
Female
;
Humans
;
In Situ Hybridization, Fluorescence
;
Kidney Neoplasms/genetics*
;
Lung Neoplasms
;
Male
;
Oncogene Proteins, Fusion/genetics*
;
Retrospective Studies
6.Relationship between EGFR, ALK Gene Mutation and Imaging and Pathological Features in Invasive Lung Adenocarcinoma.
He YANG ; Zicheng LIU ; Hongya WANG ; Liang CHEN ; Jun WANG ; Wei WEN ; Xinfeng XU ; Quan ZHU
Chinese Journal of Lung Cancer 2022;25(3):147-155
BACKGROUND:
At present, the research progress of targeted therapy for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene mutations in lung adenocarcinoma is very rapid, which brings new hope for the treatment of advanced lung adenocarcinoma patients. However, the specific imaging and pathological features of EGFR and ALK gene mutations in adenocarcinoma are still controversial. This study will further explore the correlation between EGFR, ALK gene mutations and imaging and pathological features in invasive lung adenocarcinoma.
METHODS:
A total of 525 patients with lung adenocarcinoma who underwent surgery in our center from January 2018 to December 2019 were included. According to the results of postoperative gene detection, the patients were divided into EGFR gene mutation group, ALK gene mutation group and wild group, and the EGFR gene mutation group was divided into exon 19 and exon 21 subtypes. The pathological features of the mutation group and wild group, such as histological subtype, lymph node metastasis, visceral pleural invasion (VPI) and imaging features such as tumor diameter, consolidation tumor ratio (CTR), lobulation sign, spiculation sign, pleural retraction sign, air bronchus sign and vacuole sign were analyzed by univariate analysis and multivariate Logistic regression analysis to explore whether the gene mutation group had specific manifestations.
RESULTS:
EGFR gene mutation group was common in women (OR=2.041, P=0.001), with more pleural traction sign (OR=1.506, P=0.042), and had little correlation with lymph node metastasis and VPI (P>0.05). Among them, exon 21 subtype was more common in older (OR=1.022, P=0.036), women (OR=2.010, P=0.007), and was associated with larger tumor diameter (OR=1.360, P=0.039) and pleural traction sign (OR=1.754, P=0.029). Exon 19 subtype was common in women (OR=2.230, P=0.009), with a high proportion of solid components (OR=1.589, P=0.047) and more lobulation sign (OR=2.762, P=0.026). ALK gene mutations were likely to occur in younger patients (OR=2.950, P=0.045), with somking history (OR=1.070, P=0.002), and there were more micropapillary components (OR=4.184, P=0.019) and VPI (OR=2.986, P=0.034) in pathology.
CONCLUSIONS
The EGFR and ALK genes mutated adenocarcinomas have specific imaging and clinicopathological features, and the mutations in exon 19 or exon 21 subtype have different imaging features, which is of great significance in guiding the clinical diagnosis and treatment of pulmonary nodules.
Adenocarcinoma of Lung/genetics*
;
Aged
;
Anaplastic Lymphoma Kinase/genetics*
;
ErbB Receptors/genetics*
;
Female
;
Genes, erbB-1
;
Humans
;
Lung Neoplasms/pathology*
;
Mutation
;
Tomography, X-Ray Computed/methods*
7.A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene.
Yue YUAN ; Zheng WANG ; Xin NIE ; Ping ZHANG ; Lin LI
Chinese Journal of Lung Cancer 2022;25(9):696-700
Anaplastic lymphoma kinase (ALK) fusion gene is an important tumor driver gene of non-small cell lung cancer, accounting for about 5% of patients with non-small cell lung cancer, of which 97% are patients with lung adenocarcinoma. Since the first discovery of echinoderm microtubule associated protein-like 4 (EML4)-ALK fusion in patients with lung adenocarcinoma in 2007, a variety of ALK fusion partners have been detected. CLIP1-ALK fusion gene was detected by next generation sequencing (NGS) in this patient with advanced lung squamous cell carcinoma, and Alectinib and Ensartinib were taken orally on May 5, 2021. Aletinib was effective for this patient but the patients died on September 30, 2021. This is a report of lung squamous cell carcinoma patients with CLIP1-ALK fusion gene treated with ALK inhibitors.
.
Adenocarcinoma of Lung
;
Anaplastic Lymphoma Kinase/genetics*
;
Carcinoma, Non-Small-Cell Lung/pathology*
;
Carcinoma, Squamous Cell/genetics*
;
Humans
;
Lung/pathology*
;
Lung Neoplasms/pathology*
;
Microtubule-Associated Proteins/genetics*
;
Oncogene Proteins, Fusion/genetics*
;
Protein Kinase Inhibitors/pharmacology*
;
Receptor Protein-Tyrosine Kinases/genetics*
8.Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer.
Peng SONG ; Li ZHANG ; Congcong SHANG
Chinese Journal of Lung Cancer 2018;21(9):703-711
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work.
.
Anaplastic Lymphoma Kinase
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
Drug Resistance, Neoplasm
;
genetics
;
Gene Fusion
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
Protein Kinase Inhibitors
;
pharmacology
;
therapeutic use
;
Receptor Protein-Tyrosine Kinases
;
antagonists & inhibitors
;
genetics
9.Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation Treated with Ensartinib: A Case Report and Literature Review.
Donglai LV ; Chunwei XU ; Chong WANG ; Qiuju SANG
Chinese Journal of Lung Cancer 2023;26(1):78-82
Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer. Anaplastic lymphoma kinase (ALK)-positive NSCLC accounts for only 2%-5% of all NSCLC cases, and is almost exclusively detected in patients with lung adenocarcinoma. Thus, ALK testing is not routinely performed in the LSCC population, and the efficacy of such treatment for ALK-rearranged LSCC remains unknown. Echinoderm microtubule associated protein like 4 (EML4)-ALK (V1) and TP53 co-mutations were identified by next generation sequencing (NGS) in this patient with advanced LSCC. On December 3, 2020, Ensatinib was taken orally and the efficacy was evaluated as partial response (PR). The progression-free survival (PFS) was 19 months. When the disease progressed, the medication was changed to Loratinib. To our knowledge, Enshatinib created the longest PFS of ALK-mutant LSCC patients treated with targeted therapy since literature review. Herein, we described one case treated by Enshatinib involving a patient with both EML4-ALK and TP53 positive LSCC, and the relevant literatures were reviewed for discussing the treatment of this rare disease.
.
Humans
;
Carcinoma, Non-Small-Cell Lung/drug therapy*
;
Lung Neoplasms/pathology*
;
Anaplastic Lymphoma Kinase/metabolism*
;
Carcinoma, Squamous Cell/genetics*
;
Mutation
;
Cytoskeletal Proteins/genetics*
;
Lung/pathology*
;
Oncogene Proteins, Fusion/genetics*
;
Protein Kinase Inhibitors/therapeutic use*
;
Tumor Suppressor Protein p53/genetics*
10.Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant Organ Metastasis in Non-small Cell Lung Cancer.
Chinese Journal of Lung Cancer 2018;21(7):536-542
Lung cancer is the leading cause of morbidity and mortality of malignant diseases in China. Approximately 57% lung cancer patients harbored distant metastases at initial diagnosis which is relevant to poor outcomes. The research strategy of anti-lung cancer metastasis now has became the new treatment directions and thoughts for lung cancer treatment. Previous studies have shown that changes in the corresponding driving genes on different signaling pathways may be related to the transfer of different organs, and the biological alteration of tumor to some extent can affect the metastatic behavior and metastatic pattern of tumor. However, current clinical and basic studies have not elucidated the molecular mechanism of the specific distant organ metastasis in the pathway of lung cancer related signal transduction, clinical research on the correlation between gene mutation and organ transfer specificity is also relatively rare. This review aims to summarize the characteristics of the expression of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) in non-small cell lung cancer, and the correlation between the distribution of metastatic organs.
.
Anaplastic Lymphoma Kinase
;
Carcinoma, Non-Small-Cell Lung
;
genetics
;
pathology
;
ErbB Receptors
;
genetics
;
Humans
;
Lung Neoplasms
;
genetics
;
pathology
;
Neoplasm Metastasis
;
Proto-Oncogene Proteins p21(ras)
;
genetics
;
Receptor Protein-Tyrosine Kinases
;
genetics